Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CLECL1P encodes a type II transmembrane, C-type lectin-like protein but is classified as a pseudogene. While the protein may theoretically act as a T-cell co-stimulatory molecule involved in immune response regulation and interleukin-4 production, it is not considered a functional protein-coding gene, and no direct roles in health, disease, or as a therapeutic target have been established. It is not a canonical drug target. Pseudogenes may have limited or no protein expression and very limited, if any, biological effect. The standard therapeutic, diagnostic, or biomarker roles do not apply to this gene[1]. This target is **not a functional receptor or molecule for therapeutic intervention**, but rather a non-functional pseudogene, and should not be included as a target in structure–activity, therapeutic, or mechanistic databases[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-type lectin domain family 1, member A pseudogene (CLECL1P).